by Plus Therapeutics | Feb 4, 2025 | GBM, LM, PBC, Uncategorized
Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...
by Plus Therapeutics | Feb 1, 2025 | GBM, LM, PBC, Uncategorized
A Heartfelt Thank You to Our ReSPECT-GBM & ReSPECT-LM Clinical Trial Participants To every patient who has participated in the ReSPECT-GBM and ReSPECT-LM clinical trials: THANK YOU! 💙 Your courage and commitment are helping advance critical research for recurrent...
by Plus Therapeutics | Jan 16, 2025 | LM
ReSPECT-LM Clinical Trial: Now Featured on MBCBrainMets.org! 📢 Exciting news! The ReSPECT-LM Clinical Trial is now a featured clinical trial on MBCBrainMets.org, a trusted resource hub for breast cancer patients living with brain metastases. 🔎 Learn more about the...
by Plus Therapeutics | Jan 10, 2025 | LM
Did You Know? Leptomeningeal Metastases (LM) Rise From Various Cancers Leptomeningeal metastases (LM) is a serious condition where cancer cells spread to the leptomeninges, the membranes that cover the brain and spinal cord. While any cancer can metastasize to the...
by Plus Therapeutics | Jan 7, 2025 | LM
🚀 Plus Therapeutics Doubles ReSPECT-LM Clinical Trial Locations in 2024 Plus Therapeutics is proud to announce that we have doubled the number of locations for our ReSPECT-LM clinical trial in 2024, expanding to 6 investigation sites nationwide. This significant...
by Plus Therapeutics | Dec 17, 2024 | LM
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data at 2024 San Antonio Breast Cancer Symposium (SABCS) ICYMI: Plus Therapeutics presented our ReSPECT-LM Phase 1 interim data for Breast Cancer patients with Leptomeningeal Metastases at the 2024 San...
Recent Comments